FZAMX
Price
$29.83
Change
+$0.01 (+0.03%)
Updated
Jul 31 closing price
Net Assets
2.29B
VEXMX
Price
$179.20
Change
-$0.73 (-0.41%)
Updated
Jul 31 closing price
Net Assets
97.68B
Interact to see
Advertisement

FZAMX vs VEXMX

FZAMX vs VEXMX Comparison Chart in %
View a ticker or compare two or three
VS
FZAMX vs. VEXMX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FZAMX is a Buy and VEXMX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEXMX has more cash in the bank: 97.7B vs. FZAMX (2.29B). VEXMX pays higher dividends than FZAMX: VEXMX (0.90) vs FZAMX (0.28). FZAMX was incepted earlier than VEXMX: FZAMX (13 years) vs VEXMX (39 years). FZAMX (0.58) is less costly to investors than VEXMX (0.19). FZAMX is a more actively managed with annual turnover of: 62.00 vs. VEXMX (12.00). FZAMX has a lower initial minimum investment than VEXMX: FZAMX (0) vs VEXMX (3000). FZAMX annual gain was more profitable for investors over the last year : 24.25 vs. VEXMX (19.71). VEXMX return over 5 years is better than : 28.12 vs. FZAMX (17.54).
FZAMXVEXMXFZAMX / VEXMX
Total Expense Ratio0.580.19305%
Annual Report Gross Expense Ratio0.580.19305%
Fund Existence13 years39 years-
Gain YTD20.86713.033160%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.29B97.7B2%
Annual Yield % from dividends0.280.9031%
Returns for 1 year24.2519.71123%
Returns for 3 years36.5151.7571%
Returns for 5 years17.5428.1262%
Returns for 10 years62.66174.9236%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HPS14.220.03
+0.21%
John Hancock Preferred Income Fund III
DEM53.700.10
+0.19%
WisdomTree Emerging Markets High Div ETF
MYCI24.68-0.01
-0.06%
State Street® My2029 Corporate Bond ETF
DVXP25.85-0.12
-0.45%
WEBs Consumer Staples XLP Dfnd Vol ETF
BIB96.61-3.71
-3.70%
ProShares Ultra Nasdaq Biotechnology